Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer

被引:34
作者
Chesson, Charles B. [1 ,2 ]
Zloza, Andrew [1 ,2 ]
机构
[1] Rutgers Canc Inst New Jersey, Div Surg Oncol, Sect Surg Oncol Res, New Brunswick, NJ 08903 USA
[2] State Univ New Jersey, Rutgers Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA
关键词
cancer; immunotherapy; nanoparticles; tumor antigens; vaccines; T-CELL RESPONSES; DENDRITIC CELLS; IN-VIVO; DRUG-DELIVERY; POLYMER NANOPARTICLES; ANTITUMOR IMMUNITY; INFLUENZA VIROSOME; SIPULEUCEL-T; MURINE MODEL; LYMPH-NODE;
D O I
10.2217/nnm-2017-0254
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The major goal of immunity is maintaining host survival. Toward this, immune cells recognize and eliminate targets that pose a danger. Primarily, these are external invaders (pathogens) and internal invaders (cancers). Their recognition relies on distinguishing foreign components (antigens) from self-antigens. Since cancer cells are the host's own cells that are harmfully altered, they are difficult to distinguish from normal self. Furthermore, the antigens least resembling the host are often sequestered in parts of the tumor least accessible to immune responses. Therefore, to sufficiently boost immunity, these tumor antigens must be exposed to the immune system. Toward this, nanoparticles provide an innovating means of tumor antigen presentation and are destined to become an integral part of cancer immunotherapy.
引用
收藏
页码:2693 / 2706
页数:14
相关论文
共 117 条
  • [1] An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice
    Abdoli, Asghar
    Soleimanjahi, Hoorieh
    Kheiri, Masoumeh Tavassoti
    Jamali, Abbas
    Mazaheri, Vahideh
    Alitappeh, Meghdad Abdollahpour
    [J]. PATHOGENS AND DISEASE, 2014, 72 (03): : 197 - 207
  • [2] Cytotoxic Immunotherapy Strategies for Cancer: Mechanisms and Clinical Development
    Aguilar, Laura K.
    Guzik, Brian W.
    Aguilar-Cordova, Estuardo
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (08) : 1969 - 1977
  • [3] Allison MED, 2000, EUR J IMMUNOL, V30, P2881, DOI 10.1002/1521-4141(200010)30:10<2881::AID-IMMU2881>3.0.CO
  • [4] 2-9
  • [5] In vivo Gold Nanoparticle Delivery of Peptide Vaccine Induces Anti-Tumor Immune Response in Prophylactic and Therapeutic Tumor Models
    Almeida, Joao Paulo Mattos
    Lin, Adam Yuh
    Figueroa, Elizabeth Raquel
    Foster, Aaron Edward
    Drezek, Rebekah Anna
    [J]. SMALL, 2015, 11 (12) : 1453 - 1459
  • [6] Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein - A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation
    Anderson, MM
    Hazen, SL
    Hsu, FF
    Heinecke, JW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (03) : 424 - 432
  • [7] Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice
    Ballester, Marie
    Jeanbart, Laura
    de Titta, Alexandre
    Nembrini, Chiara
    Marsland, Benjamin J.
    Hubbell, Jeffrey A.
    Swartz, Melody A.
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [8] Bourla AB, 2016, ONCOLOGY-NY, V30, P59
  • [9] Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine
    Bryan, Janine T.
    Buckland, Barry
    Hammond, Jennifer
    Jansen, Kathrin U.
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2016, 32 : 34 - 47
  • [10] Buonaguro L, 2011, EXPERT REV VACCINES, V10, P1569, DOI [10.1586/ERV.11.135, 10.1586/erv.11.135]